X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
2-chlorodeoxyadenosine (766) 766
humans (641) 641
hematology (386) 386
oncology (364) 364
male (348) 348
cladribine (304) 304
female (297) 297
middle aged (294) 294
aged (265) 265
adult (246) 246
cladribine - therapeutic use (232) 232
antineoplastic agents - therapeutic use (167) 167
leukemia, hairy cell - drug therapy (163) 163
treatment outcome (148) 148
chronic lymphocytic-leukemia (145) 145
therapy (144) 144
index medicus (143) 143
cladribine - administration & dosage (139) 139
fludarabine (129) 129
cladribine - adverse effects (125) 125
hairy cell leukemia (122) 122
pentostatin (112) 112
leukemia (111) 111
toxicity (107) 107
hairy-cell leukemia (103) 103
remission induction (103) 103
leukemia, lymphocytic, chronic, b-cell - drug therapy (101) 101
2-chloro-2'-deoxyadenosine (93) 93
aged, 80 and over (92) 92
antineoplastic combined chemotherapy protocols - therapeutic use (89) 89
term-follow-up (84) 84
cladribine - pharmacology (80) 80
vidarabine - analogs & derivatives (79) 79
pharmacology & pharmacy (77) 77
recurrence (77) 77
antineoplastic agents - adverse effects (76) 76
rituximab (72) 72
follow-up studies (70) 70
apoptosis (69) 69
minimal residual disease (66) 66
2-cda (63) 63
antineoplastic agents - administration & dosage (60) 60
cancer (60) 60
pentostatin - therapeutic use (60) 60
leukemia, hairy cell - pathology (58) 58
interferon (57) 57
antineoplastic agents - pharmacology (56) 56
deoxycytidine kinase (55) 55
disease-free survival (55) 55
non-hodgkins-lymphoma (55) 55
remission (55) 55
animals (54) 54
chronic lymphocytic leukemia (54) 54
chemotherapy (53) 53
complete remission (49) 49
lymphoma (48) 48
survival rate (48) 48
tumor cells, cultured (48) 48
drug administration schedule (47) 47
malignancies (47) 47
agent (46) 46
biochemistry & molecular biology (44) 44
human-lymphocytes (44) 44
immunosuppressive agents - therapeutic use (44) 44
induction (44) 44
retrospective studies (44) 44
survival analysis (44) 44
remissions (43) 43
splenectomy (43) 43
vidarabine - therapeutic use (41) 41
acute myeloid-leukemia (40) 40
combination (40) 40
infusions, intravenous (40) 40
time factors (40) 40
lymphoma, non-hodgkin - drug therapy (39) 39
prognosis (39) 39
drug resistance, neoplasm (38) 38
expression (38) 38
analogs (37) 37
cells (37) 37
medicine, general & internal (37) 37
term follow-up (37) 37
deoxyadenosine (36) 36
interferon-alpha - therapeutic use (36) 36
waldenstrom macroglobulinemia - drug therapy (36) 36
dose-response relationship, drug (35) 35
langerhans cell histiocytosis (35) 35
leukemia, hairy cell - diagnosis (35) 35
leukemia, hairy cell - mortality (34) 34
leukemia, hairy cell - therapy (33) 33
medicine & public health (33) 33
nucleoside analogs (33) 33
2'-deoxycoformycin (32) 32
antineoplastic combined chemotherapy protocols - adverse effects (32) 32
leukemia, lymphocytic, chronic, b-cell - pathology (32) 32
phase-ii trial (32) 32
apoptosis - drug effects (31) 31
phase-ii (31) 31
salvage therapy (31) 31
2-chloroadenosine - analogs & derivatives (30) 30
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (829) 829
Czech (9) 9
Polish (9) 9
French (7) 7
German (7) 7
Russian (5) 5
Spanish (5) 5
Korean (2) 2
Japanese (1) 1
Portuguese (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


JAAD Case Reports, ISSN 2352-5126, 11/2018, Volume 4, Issue 10, pp. 990 - 992
Journal Article
Leukemia & Lymphoma, ISSN 1042-8194, 09/1999, Volume 35, Issue 1-2, pp. 171 - 177
It has been observed that some patients in complete remission (CR) after 2-chlorodeoxyadenosine (2-CdA) for hairy cell leukemia (HCL) have hypocellular bone... 
2-chlorodeoxyadenosine
Journal Article
Leukemia & Lymphoma, ISSN 1042-8194, 07/1999, Volume 34, Issue 3-4, pp. 335 - 340
This study was designed to investigate the immunostimulatory effect of low dose Il-2 treatment in B-CLL patients previously treated with 2-chlorodeoxyadenosine... 
2-chlorodeoxyadenosine
Journal Article
MULTIPLE SCLEROSIS JOURNAL, ISSN 1352-4585, 10/2018, Volume 24, Issue 12, pp. 1617 - 1626
Objective: This propensity score-matched analysis from MSBase compared the effectiveness of cladribine with interferon , fingolimod or natalizumab. Methods: We... 
CONTROLLED-TRIAL | disability | MS | relapses | interferon | NEUROSCIENCES | CLINICAL NEUROLOGY | ORAL CLADRIBINE | fingolimod | Cladribine | 2-CHLORODEOXYADENOSINE | OUTCOMES | natalizumab
Journal Article
Clinical Pharmacokinetics, ISSN 0312-5963, 03/2019, Volume 58, Issue 3, pp. 283 - 297
Cladribine Tablets (MAVENCLAD (R)) are used to treat relapsing multiple sclerosis (MS). The recommended dose is 3.5 mg/kg, consisting of 2 annual courses, each... 
NUCLEOSIDE TRANSPORTERS | CELLS | PLASMA | ORAL CLADRIBINE | PHARMACOKINETICS | DISABILITY STATUS SCALE | PHARMACOLOGY & PHARMACY | 2-CHLORODEOXYADENOSINE | TIME | CYTOTOXICITY | Multiple sclerosis | Leukemia | Clinical trials | Pharmacology | Breast cancer | Bioavailability | Kinases | Patients | Studies | Proteins | Neurology | Lymphocytes | Drug dosages | Immune system | Review
Journal Article
Blood, ISSN 0006-4971, 02/2017, Volume 129, Issue 5, pp. 553 - 560
Journal Article
Journal Article
Multiple Sclerosis and Related Disorders, ISSN 2211-0348, 04/2019, Volume 29, pp. 168 - 174
Immune reconstitution therapies (IRT) for patients with multiple sclerosis are used for short, intermittent treatment periods to induce immune resetting and... 
Cladribine tablets | Efficacy | Safety | Lymphocytes | ALEMTUZUMAB | PLACEBO | CLARITY | 2-CHLORODEOXYADENOSINE | RECONSTITUTION | CANCER | CLINICAL NEUROLOGY
Journal Article
Journal Article
BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY, ISSN 1521-6926, 12/2015, Volume 28, Issue 4, pp. 269 - 272
This brief review highlights the sequence of therapeutic milestones and advances in our understanding of the biology of hairy cell leukemia (HCL) with a focus... 
SURVIVAL | PENTOSTATIN | DIAGNOSIS | BRAF V600E MUTATION | FOLLOW-UP | BRAF | VARIANT | CLADRIBINE | Vemurafenib | Hairy cell leukemia | 2-CHLORODEOXYADENOSINE | HEMATOLOGY | MINIMAL RESIDUAL DISEASE | REMISSION
Journal Article
Blood Reviews, ISSN 0268-960X, 09/2018, Volume 32, Issue 5, pp. 387 - 399
Chronic lymphocytic leukemia (CLL) is the most common adult leukemia in the world. Patient with CLL are at particular risk for infections due to inherent... 
Chronic lymphocytic leukemia | CLL | Targeted therapy | Idelalisib | Ibrutinib | Venetoclax | PLUS RITUXIMAB | OPEN-LABEL | MONOCLONAL-ANTIBODY | B-VIRUS REACTIVATION | PREVIOUSLY UNTREATED PATIENTS | PHASE-II TRIAL | 2-CHLORODEOXYADENOSINE CLADRIBINE | INITIAL THERAPY | 1ST-LINE THERAPY | HEMATOLOGY | ELDERLY-PATIENTS
Journal Article